Heterogeneity of treatment effects by risk in pulmonary arterial hypertension.

ABSTRACT:

Background

It is currently unknown if disease severity modifies response to therapy in pulmonary arterial hypertension (PAH). We aimed to explore if disease severity, as defined by established risk-prediction algorithms, modified response to therapy in randomised clinical trials in PAH.

Methods

We performed a meta-analysis using individual participant data from 18 randomised clinical trials of therapy for PAH submitted to the United States Food and Drug Administration to determine if predicted risk of 1-year mortality at randomisation modified the treatment effect on three outcomes: change in 6-min walk distance (6MWD), clinical worsening at 12 weeks and time to clinical worsening.

Results

Of 6561 patients with a baseline US Registry to Evaluate Early and Long-Term PA

SUBMITTER: Pan HM 

PROVIDER: S-EPMC10919241 | biostudies-literature | 2023 Jul

REPOSITORIES: biostudies-literature